Cerenome, Inc.

Cerenome, Inc.

CNSY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$4.27M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Cerenome, Inc.Cerenome, Inc.0--478%-0.6-
$0.41

Current Fair Value

35.4% downside

Overvalued by 35.4% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$4.27 Million
Enterprise Value$1.95 Million
Earnings per Share$-7.19
Beta1.49
Outstanding Shares6,773,125

Return

Return on Equity-477.54%ROE
Return on Assets-185.94%
Return on Invested Capital366.70%

Valuation & Multiples

P/E Ratio0P/E Ratio
PEG0PEG
Price to Sales-0.63Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-0.4
Enterprise Value to EBIT0.1
Enterprise Value to Net Income-1
Total Debt to Enterprise0.02
Debt to Equity0.01Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 13, 2026
EPS
-$1.14
Est. -$0.95
Revenue
$722,000
Est. $920,333

Next Earnings Call

Expected Date
February 25, 2027
EPS Estimate
-$0.86
Consensus analyst estimate
Revenue Estimate
$2.01 M
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %2.29%▲ 2.29%
Total Invested$289,455
Investors Holding10▲ 10.00%

About Plus Therapeutics Inc

2,018 employees
CEO: Marc Hedrick

Plus Therapeutics is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company's drug development is a unique na...